BMS-986354

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

BCMA-targeted CAR-T immunotherapy

Related drugs:

‹

›

4ms

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)

P1, N=78, Completed, Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting --> Completed | N=150 --> 78 | Trial completion date: Jun 2025 --> Jul 2024 | Trial primary completion date: Jun 2025 --> Jul 2024

4 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

cyclophosphamide • BMS-986354

2years

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (ASH 2022)

Pts received a single BMS-986354 infusion 2–7 days after lymphodepleting chemotherapy (3 days fludarabine [30 mg/m2] and cyclophosphamide [300 mg/m2])...Median onset was day 4 (range, 2–8), median duration was 4 days (range, 1–8), and common treatments included tocilizumab (n = 38), steroids (n = 25), and anakinra (n = 9)... BMS-986354, a NEX-T investigational BCMA-targeted CAR T-cell product, is a less differentiated, more potent cellular drug product than orva-cel and can be manufactured with a more rapid processing time. At low doses, BMS-986354 demonstrated a favorable safety profile and promising efficacy, including deep and durable responses in pts with heavily pretreated RRMM. The study continues to enroll patients in the dose-expansion phase.

2 years ago

Clinical • P1 data

IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)

cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • BMS-986354 • Kineret (anakinra) • orvacabtagene autoleucel (JCARH125)